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Original Article
High Tissue Factor Microparticle Level in Major Thalassemic Patients 
with Pulmonary Hypertension
Abstract  Objective: To analyze the correlation between tissue factor microparticles 
(TF-MP) levels and pulmonary hypertension (PH) in adult thalassemic 
patients.
 Methods: This study was conducted from September to October 2018, 
using secondary and primary data. The secondary data consisted of the PH 
parameter, which was retrieved from a 2017 previous study entitled ‘Clinical 
Characteristic and Complication due to Iron Overload in Thalassaemic 
Patients‘in 2017 while the primary data were the TF-MP which were 
obtained from the analysis of frozen serum of the same population using 
ELISA method. The mean pulmonary arterial pressure (mPAP) values were 
obtained from echocardiography results and PH was defined as mPAP >25 
mmHg.
 Results: Seven (16.7%) major thalassemic patients experienced PH. The 
median values of TF-MP levels were higher among major thalassemic 
patients with PH when compared to the non-PH patients (1569 vs 11.5 pg/
dL; p=0.023). No significant difference was observed in the median TF-MP 
levels between subjects with splenectomy and subjects without splenectomy 
(11.6 vs 12.3 pg/dL; p=0.44). There was also no difference in mPAP values 
between subjects with splenectomy and subjects without splenectomy (18.0 
vs 17.0 mmHg; p=0.663). When the median TF-MP levels among major 
thalassemic patients were analyzed in terms of correlation with transfussion 
level, no statistically significant difference was seen between subjects who 
received sufficient transfusions (≥180 mL/kgbb/year) and those who 
received insufficient transfusions (<180 mL/kgbb/year) (r = 0.138; p=0.390).
 Conclusions: There is a positive correlation between the TF-MP levels and 
PH in adult major thalassemic subjects.
                Keywords: Major thalassemia, pulmonary hypertension, tissue factor 
microparticles 
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Introduction 
Homozygous β-globin carrier defects in 
thalassemia patients can give rise to several 
complications due to hemolysis, chronic 
anemia, and continuous transfusions. In 
the last few decades, major thalassemia 
patients can live longer with the availability 
of blood transfusion and iron chelation. 
With the longer survival, the previously 
unrecognized complications associated with 
hypercoagulability become visible.1,2 
  Complications associated with 
hypercoagulability appear to be subclinical, 
marked only by changes in the hemostasis 
parameters, until thromboembolic processes 
such as stroke, transient ischemic attack, 
deep vein thrombosis (DVT), and pulmonary 
embolism occur. Pulmonary hypertension 
(PH) in thalassemia is included in the 5th class 
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of the PH classification of the 2013 American 
College of Cardiology and is considered to 
happen via multifactorial mechanisms. It is 
considered as the complication that becomes 
the main factor of morbidity and mortality 
in these patients. Pulmonary hypertension 
involves several mechanisms such as 
endothelial dysfunction, inflammation, and 
chronic thromboembolism. The mechanism 
of thromboembolism in thalassemia patients 
with PH has not been clearly understood.3, 4 
The multifactorial mechanism requires 
microparticles to play distinctive roles 
in the cellular interactions related to PH 
pathogenesis. Microparticles are vesicles from 
the plasma membrane, ranging from 0.1 to 1 
µm in size, that are released by cells through 
activation by their agonists, physical and 
chemical stresses, and apoptosis. Tissue factor 
microparticles (TF-MP) or circulating Tissue 
factor (cTF) is a protein released by cellular 
activation or apoptosis that plays an important 
role in producing thrombin in the propagation 
phase of the cell-based coagulation. Cellular 
activation in thalassemia is caused by 
negatively-charged cell membranes and 
hemolysis process disorders. Previous studies 
have reported that increased TF-MP levels are 
found in thalassemia patients, as well as in 
patients with 1st and 3rd group PH.5, 6
No data available yet on the roles of TF-MP 
in thalassemia patients with PH. This study 
aimed to analyze the correlation between 
TF-MP level and PH in major thalassemia 
patients in Dr. Hasan Sadikin General Hospital, 
Bandung, West Java, Indonesia.
Methods
 
This was a cross-sectional quantitative study 
using numeric-numeric correlative statistical 
analysis conducted from September to October 
2018. Subjects in the study were thalassemia 
patients treated at the Hematology-Medical 
Oncology Clinic, Internal Medicine Department, 
Faculty of Medicine, Universitas Padjadjaran/
Dr. Hasan Sadikin General Hospital Bandung. 
PH parameters were collected as secondary 
data from a previous study entitled ‘ Clinical 
Characteristic and Complication due to Iron 
Overload in Thalassaemic Patients ‘ which was 
conducted in 2017 while data on TF-MP were 
collected by testing the frozen serum of the 
same population of this 2017 study. 
The inclusion criteria were thalassemia 
patients aged ≥14 years who had received 
treatments and regular transfusions for 
more than two years after diagnosis, had 
echocardiographic data, and had their frozen 
serum stored. The exclusion criteria were 
intermediate thalassemia patients and patients 
with left ventricular or left atrial hypertrophy. 
Pulmonary hypertension (PH) was measured 
using the GE Vivid S6 echocardiography device. 
Meanwhile, the severity of PH was determined 
by estimating the mean Pulmonary Arterial 
Pressure (mPAP) (≥25 mmHg). The mPAP 
was measured while the patient was resting 
through the use of the Pulmonary Velocity 
Accelerated Time (PVaccT) calculation [mPAP 
=80-(PVaccT/2)]. Data on the MP-TF levels 
were collected through subject serum analysis 
using the ELISA method and the results were 
reported in pg/dL.
Before statistical analyses were performed, 
data normality testing was performed 
on numerical data, such as age, period of 
suffering from thalassemia, transfusion 
period, total transfusions volume, sufficiency 
of transfusions, ferritin levels, Hemoglobin 
(Hb) levels, thrombocyte counts, mPAP values, 
and TF-MP levels. The Shapiro-Wilk test was 
selected for this testing because the number of 
subjects was less than 50. Data on age, ferritin 
levels, hematocrit percentages, thrombocyte 
counts, ferritin levels, period of suffering from 
thalassemia, sufficiency of transfusions, mPAP 
values, and MP-TF levels were not normally 
distributed (p>0.05), while data on Hb level 
were normally distributed (p>0.05).
Normally distributed data were presented 
in mean and analyzed using Pearson 
correlation (r) test, while data that were 
not normally distributed were presented in 
median and analyzed using non-parametric 
Spearman correlation test (rs). Point biserial 
correlation (rpb) analysis was performed to 
observe the correlation between numerical 
and categorical data. Results were declared as 
significant if p<0.05. 
Results
 
Subject characteristics, including age, sex, 
ferritin levels, Hb levels, Ht percentages, 
thrombocyte counts, sufficiency of 
transfusions, numbers of subjects with PH or 
without PH, mPAP values, and TF-MP levels, 
are presented in Table 1. The median age was 
20 years old. More females were included 
in the study than males (38.1% versus 
61.9%). The median period of suffering from 
thalassemia was 198 months. The sufficiency 
of transfusion was 65.6 cc/kgBW/year while 
the mean Hb level, median thrombocyte count, 
and median ferritin level were 7.0±1.3 g/dL, 
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137,000, and 3,940 ng/dL, respectively.
The subjects characteristics including 
the age, sex, ferritin levels, Hb levels, Ht 
percentages, thrombocyte counts, sufficiency 
of transfusions, numbers of subjects with PH 
or without PH, mPAP values, and TF-MP levels 
can be seen in Table 1 below. The median of 
age was 20, consisting of males (38.1%) and 
females (61.9%). The median of period of 
suffering from thalassemia was 198 months. 
The sufficiency of transfusions was 65,6 cc/
kgbb/year, the mean of Hb level was 7.0±1.3 
g/dL, the median of thrombocyte count was 
137.000, and the median of ferittin level was 
3940 ng/dL.
When the correlation between MP-TF 
level and mPAP value was assessed using 
the Spearman correlation test with a 95% 
confidence interval, it was revealed that the 
MP-TF level had a statistically significant 
correlation with the mPAP value (r=0.481; 
p=0.001). (r=0.481; p=0.001).
Discussion
This study presented a correlation between 
Table Study Subject Basic Characteristics 
Variable n=42                            
Age (years old), median (min–max) 20 (16–36)
Sex, n (%)
     Male 16 (38.1)
     Female 26 (61.9)
Period of suffering from thalassemia (months), median (min–max) 198 (68–291)
Group, n (%)
     Splenectomy 12 (28.6)
     Non-splenectomy 30 (71.4)
Hb (g/dL), mean±SD 7.0±1.3
Hb category
     <9 g/dL 40 (95.2)
     ≥9 g/dL 2 (4.8)
Ht (%), median (min–max) 22.0 (9.1–51.9)
Thrombocyte count (x1000/mm3 ), median (min–max) 137 (18–903)
Ferritin ng/dL, median (min–max) 3940 (948–14030)
Ferritin category ng/dL, n (%) (ng/dL)
     <2,500 13 (31.0)
     ≥2,500 29 (69.0)
Sufficiency of transfusion (mL/kgbb/year), median (min–max) 65.6 (0.0–339.9)
Sufficiency of transfusion category, n (%) n=41
     ≥180 mL/kgbb/year 5 (11.9)
     <180 mL/kgbb/year 36 (85.7)
PH and non-PH group
     PH 7 (16.7)
     Non-PH 35 (83.3)
 mPAP (mmHg), median (min–max) 17.0 (9.0–43.0)
 MP-TF (pg/dL), median (min–max) 12.1 (5.3–2615.2)
Note: SD= Standard deviation, n= total, %=Percentage
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Fig 1 Scatter Diagram of Correlation between MP-TF Level and mPAP Value 
Fig. 2 Boxplot of Median MP-TF Level in PH and Non-PH Groups 
Transfusion Sufficiency
Fig. 3 Scatter Diagram of Correlation between Transfusion Sufficiency and TF-MP Level 
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increased MP-TF levels and high mPAP values 
(moderate correlation; r=0.481; p<0.001). 
Based on the point biserial analysis to observe 
a direct correlation between the MP-TF level 
and the presence of PH, a significant difference 
was observed between PH and non-PH 
subjects (p<0.05; rpb=0.311). 
A study conducted by Bakoubula et al. in 
2008 that examined the correlation between 
MP-TF levels and PH by enrolling 20 subjects 
with 1st and 3rd group of PH discovered a 
statistically significant correlation between 
the MP-TF level and PH (p<0.001). Dhiel et al. in 
2010 who studied 19 subjects with PH caused 
by chronic thromboembolism, idiopathic PH, 
rheumatic-related PH, and chronic pulmonary 
disease (CPD)-related PH also found a positive 
correlation between procoagulant MP level 
and occurrence of PH in study subjects when 
compared to the normal control.7, 8 
Hypercoagulability complications in 
thalassemia patients are characterized by 
Splenectomy Non-Splenectomy
Groups
Fig. 4 Boxplot of TF-MP Level in Splenectomy and Non-splenectomy Groups
Fig. 5 Boxplot of mPAP Levels in Splenectomy and Non-splenectomy Groups
Splenectomy Non-Splenectomy
Groups
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subclinical defects marked by hemostasis 
parameter changes until the occurrence 
of thromboembolic events such as stroke, 
transient ischemic attack, DVT, and chronic 
pulmonary embolism. The PH in thalassemia 
can be included in the 5th group of the 2013 
ACC classification. Pulmonary hypertension in 
thalassemia is caused by various factors and 
mechanisms, including pulmonary arteriole in 
situ thrombosis. Interactions among factors 
that play the roles in the occurrence of PH in 
major thalassemia patients require a medium 
such as procoagulant MP.5, 9 
This study reveals a correlation between MP-
TF level and mPAP value in major thalassemia 
population. This study supports findings of 
previous studies and adds supporting data of 
in situ thrombosis process in the pathogenesis 
of the 5th group PH through the roles of 
procoagulant microparticles, such as TF-MP.5
The correlation between the TF-MP level 
and PH discovered in this study is considered 
moderate (r=0.481). This may relate to other 
mechanism pathways, such as the endothelial 
dysfunction pathway, triggered by decreased 
nitric oxide and inflammation. Endothelial 
dysfunction causes an imbalance in mediator 
production, which leads to vasoconstriction, 
smooth muscle hyperplasia, and pulmonary 
arterial remodeling. Other factors that can 
influence the occurrence of PH are not 
included in this study despite the possibility 
that they may also influence the significance 
of the correlation. Hence, this is considered a 
limitation in this study.5,10
Of all thalassemia patients in this study, 
16.7% had PH. This is different from a previous 
study by Fayed et al. in 2017 which reported 
that 36% of major thalassemia children 
have PH. The presence of PH in their study 
was determined through echocardiographic 
examination by calculating mPAP using a 
different formula.11 
Based on the 2015 ESC, mPAP is not used 
for echocardiographic diagnosis of PH. Instead, 
the 2015 ESC uses the tricuspid regurgitant 
velocity (TRV) and other imaging techniques 
for assessing complications of PH in the right 
side of the heart. This method is more specific 
and widely used. The results are categorized as 
low, moderate, or high probability for PH. This 
study uses secondary data from a previous 
study. However, the reference study did not 
use TRV calculation in the determination of 
PH, which creates another limitation of this 
study.12 
The median TP-MF level of the subjects 
of this study was 12.1 pg/dL, which is much 
higher than the TP-MF level in normal people, 
which is less than 0.21 pg/dL. The increase in 
the TF-MP level in major thalassemia patients 
in comparison to the normal population is 
also demonstrated in some previous studies. 
A higher level of TF-MP can also be found in 
several other diseases such as HIV, diabetes 
mellitus, and sickle cell disease.13, 14 
The determinant factors of defect in thalassemia 
are chronic hemolysis and ineffective 
erythropoiesis with iron overload which leads 
to complications in thalassemia, including 
hypercoagulability. Hemichrome precipitation 
due to thalassemic erythrocyte globin chain 
defect can cause heme disintegration, enhance 
intracellular labile iron, and produce reactive 
oxygen species, which lead to endothelial 
activation and dysfunction.10 
The majority of the subjects in this study 
(95.2%) had a pre-transfusion Hb level of 
<9 g/dL, which was caused by insufficient 
transfusions. The median of transfusion 
sufficiency in this study was 65.6 cc/kg BW/
year, which is below the standard of ≥180 
cc/kg BW/year. No significant correlation 
was observed between the insufficiency of 
transfusions and either TF-MP level and the 
presence of PH. A previous study by Hastuti in 
Dr. Hasan Sadikin General Hospital, Bandung, 
Indonesia in 2007 on major thalassemia 
patients discovered a correlation between 
the sufficiency of transfusions and the 
hypercoagulability index when examined by 
TEG. The insufficiency of transfusions can 
cause a higher level of thalassemic erythrocyte 
cells.15 
The results of this study were different 
from the results reported by Agouti et al. in 
2015 on 37 major thalassemia patients. Their 
study described higher TF-MP in subjects 
who received insufficient transfusions, which 
was assessed using the flow cytometry test. 
Flow cytometry test is considered to be 
more sensitive and has the ability to identify 
the cell origin of TF-MP. Literature stated 
that complications due to chronic hemolysis 
and ineffective hematopoiesis in relation 
to the thromboembolic processes are more 
frequently seen in intermediate thalassemia 
than in major thalassemia. Agouti’s study does 
not include intermediate thalassemia patients 
so complications caused by insufficiency of 
transfusions do not influence the higher TF-
MP level and PH.16 
Splenectomy in thalassemia patients 
triggers an increase in thrombocyte count, 
activation, and aggregation. These conditions 
may lead to a higher level of TF-MP derived 
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from thrombocytes. Splenectomy is also 
associated with an increase in mPAP values 
in thalassemia patients and previous studies 
have discovered a higher PH incidence in 
patients with splenectomy when compared to 
those without splenectomy.11 
The result of this study showed no 
significant correlation between splenectomy 
and increased TF-MP level and mPAP value. 
A previous study stated that the incidence of 
PH is higher in thalassemia patients who had 
undergone splenectomy. The difference in 
result is probably caused by the number of 
the subjects in the study which is lower (36 
subjects) than in this study, along with the 
higher frequency (47.2%) of PH in their study. 
The mean thrombocyte count in their study is 
548.200±242.500/mm3, which is higher than 
in this study (137.000/mm3).11
Several limitations are noted in this 
current study, including PH examination 
using PvaccT calculation, which is less specific 
than other methods such as the TRV from 
echocardiography. This study does not analyze 
the origin of cells that activate and release TF-
MP, thus unable to describe the influence of 
sufficiency of transfusions on the TF-MP level. 
This study also does not analyze major factors 
that can influence the pathogenesis of PH from 
the endothelial dysfunction and inflammation 
pathways; hence, major determinants in the 
significance of the correlation between TF-
MP level and PH in major thalassemia patients 
cannot be discovered.17, 18
In summary, this study proves that the 
TF-MP level influences in situ thrombosis in 
the mechanism of PH in major thalassemia 
patients. Further studies with cohort design 
and multiple regression analysis of other 
determinant factors in the endothelial 
dysfunction and inflammation pathways that 
might contribute to the mechanism of PH 
should be conducted. In major thalassemic 
patients with sufficient transfusions, it is 
not crucial to discover the origin of cells that 
release TF-MP using flow cytometry test. 
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